Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

BIOCORP : and AgaMatrix Announce a Strategic Partnership Based on the Insulin Dose Capture Pen Cap Mallya® and AgaMatrix's Blood Glucose Monitoring Solutions

share with twitter share with LinkedIn share with facebook
02/18/2019 | 12:01pm EDT

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, and AgaMatrix, a developer and manufacturer of novel solutions for blood glucose monitoring, announce today that they have reached an agreement including binding terms for distribution in the US and European markets and co-development activities to be finalized with definitive agreements in the next 3-5 months.

The two companies operate to improve compliance for diabetic patients and decided to join their efforts for providing a unique solution on the marketplace.

BIOCORP designs, develops and manufactures Mallya® (formerly known with the project name Easylog), the add-on fitting insulin pen injectors that captures key treatment information (selected dose, date and time of injection) and transmits it to a dedicated mobile app.

On one hand, AgaMatrix gets non-exclusive rights to distribute Mallya® in the US, the UK and the EU market in the diabetes field. And BIOCORP also grants AgaMatrix exclusive rights to license and distribute the device in the US white label market.

On the other hand, BIOCORP and AgaMatrix have co-development projects to offer a breakthrough innovation combining AgaMatrix and BIOCORP expertise.

The opportunity with AgaMatrix to bring Mallya on the US and European markets is very promising and a key milestone in our strategy. Beyond that, collaborating on a specific solution together with AgaMatrix continues to position BIOCORP at the forefront of innovation and providing the most effective solution for the benefits of patients,” said Eric Dessertenne, COO of BIOCORP.

BIOCORP estimates that this contract could generate as much as 20M Euros of revenue over the next five years and will disclose more precise information and estimates in the future as the product is planned to officially reach the market in 2019*.

* These forward-looking statements are not guarantees of future performance and reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results to differ materially from any projections of future performance or result expressed or implied by these forward-looking statements.

ABOUT AGAMATRIX, Inc.
AgaMatrix, Inc. is a developer of diagnostic technologies for glucose monitoring and wholly owned subsidiary of AgaMatrix Holdings LLC. Based in New Hampshire, USA, AgaMatrix develops, manufactures and markets innovative solutions for blood glucose monitoring and data management on mobile and cloud platforms. AgaMatrix has sold over 8 million blood glucose monitors and over 3 billion test strips since the Company’s 2001 inception. For more information, please visit http://www.agamatrix.com

ABOUT BIOCORP
Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over fourteen years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including Mallya, a smart cap for pen injectors that captures injection data and automatically transmits data to a mobile app, helping patients to manage their treatment. The company has a team of 45 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com
Follow us on Twitter @BIOCORPSystems


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
Latest news on BIOCORP
06/30BIOCORP : Signs Distribution Agreement for Mallya Technology With Roche Diabetes..
BU
06/22BIOCORP : Announces Initiation of Coverage by Gilbert Dupont
BU
06/19BIOCORP : and Théa Sign a Partnership for the Development of Innovative Digital ..
BU
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
PU
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
BU
02/12BIOCORP : Strong Revenue Growth In 2019
BU
More news
Financials
Sales 2020 15,2 M 17,1 M 17,1 M
Net income 2020 0,60 M 0,67 M 0,67 M
Net cash 2020 1,19 M 1,34 M 1,34 M
P/E ratio 2020 175x
Yield 2020 0,06%
Capitalization 109 M 122 M 122 M
EV / Sales 2019
EV / Sales 2020 7,04x
Nbr of Employees 52
Free-Float 51,3%
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 31,35 €
Last Close Price 26,30 €
Spread / Highest target 21,7%
Spread / Average Target 19,2%
Spread / Lowest Target 16,7%
EPS Revisions
Managers
NameTitle
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCORP103.88%122
JOHNSON & JOHNSON-3.36%371 399
ROCHE HOLDING AG6.02%299 393
MERCK & CO., INC.-13.38%198 849
NOVARTIS AG-9.64%193 542
PFIZER, INC.-11.92%191 697